Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT32-DRL_PB vs Keytruda in adjuvant treatment of resected melanoma
2025-525093-11-00Phase 3Authorised
- Sponsor
- Alvotech
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in cutaneous melanoma (CM) (2 arms), sponsored by Alvotech. Primary endpoints: AUC0-3w Cycle 1 and AUCtau Cycle 6. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2025-525093-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525093-11-00.